At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 156 enrolled
Drug / intervention
LC350189 formulated capsule +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group, Placebo and Active Comparator-controlled, Dose Finding, and Phase II Study to Assess Efficacy and Safety of LC350189 in Gout Patients With Hyperuricemia
In Brief
A Phase 2 clinical trial evaluating LC350189 formulated capsule and Placebo for Gout and Hyperuricemia. Completed, enrolled 156 participants across 34 sites.
Detailed Summary
The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGout, Hyperuricemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartDec 2019
Primary CompletionMay 2021
Study CompletionMay 2021
TodayJul 2026
First PostedMay 1, 2019
Enrollment StartDec 2, 2019
Primary CompletionMay 3, 2021
Study CompletionMay 17, 2021
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.2 years ago
Interventions
LC350189 formulated capsuledrug
Xanthine Oxidase Inhibitor
Placebodrug
Matching placebo